title: Transdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms.
authors.forename: Melanie
authors.initials: M
authors.lastname: Hess
authors.forename: Lukas
authors.initials: L
authors.lastname: Boesch
authors.forename: Ria
authors.initials: R
authors.lastname: Leisinger
authors.forename: Rudolf
authors.initials: R
authors.lastname: Stohler
mesh_terms: D000279:Administration, Cutaneous; D000286:Administration, Sublingual; D000328:Adult; D002047:Buprenorphine / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D058850:Opiate Substitution Treatment / Q000379:methods*; D012720:Severity of Illness Index; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D002047:Buprenorphine; D008691:Methadone